Bionik Laboratories Corp. (OTCMKTS:BNKL) Files An 8-K Regulation FD Disclosure

Bionik Laboratories Corp. (OTCMKTS:BNKL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

Story continues below

On October 30, 2018, Bionik Laboratories Corp. issued a press release announcing the filing of a Registration Statement on Form S-1 (File No. 333-228044) with the U.S. Securities and Exchange Commission.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and in Item 9.01 of this report (including Exhibit 99.1) is being furnished to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 9.01 Financial Statements and Exhibits.
Exhibit Description
99.1 Press Release dated October 30, 2018


Bionik Laboratories Corp. Exhibit
EX-99.1 2 tv505818_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1         Bionik Laboratories Files Registration Statement for Proposed Follow-On Offering   TORONTO and BOSTON (October 30,…
To view the full exhibit click here

About Bionik Laboratories Corp. (OTCMKTS:BNKL)

Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., is a medical device and robotics company. The Company is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Company is also engaged in developing a lower-body exoskeleton, ARKE, which designs to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking.

An ad to help with our costs